c-Jun N-terminal Kinase Inhibitor II (SP600125) Activates Müllerian Inhibiting Substance Type II Receptor-Mediated Signal Transduction
Authors:
- 18 October 2007
- journal article
- Published by The Endocrine Society in Endocrinology
- Vol. 149 (1) , 108-115
Abstract
Müllerian inhibiting substance (MIS), the hormone required for Müllerian duct regression in fetal males, is also expressed in both adult males and females, but its physiological role in these settings is not clear. The expression of the MIS type II receptor (MISRII) in ovarian cancer cells and the ability of MIS to inhibit proliferation of these cells suggest that MIS might be a promising therapeutic for recurrent ovarian cancer. Using an MISRII-dependent activity assay in a small-molecule screen for MIS-mimetic compounds, we have identified the c-Jun N-terminal kinase inhibitor SP600125 as an activator of the MIS signal transduction pathway. SP600125 increased the activity of a bone morphogenetic protein-responsive reporter gene in a dose-dependent manner and exerted a synergistic effect when used in combination with MIS. This effect was specific for the MISRII and was not seen with other receptors of the TGFβ family. Moreover, treatment of mouse ovarian cancer cells with a combination of SP600125 and paclitaxel, an established chemotherapeutic agent used in the treatment of ovarian cancer, or with MIS enabled inhibition of cell proliferation at a lower dose than with each treatment alone. These results offer a strong rationale for testing the therapeutic potential of SP600125, alone or in combination with already established drugs, in the treatment of recurrent ovarian cancer with a much-needed decrease in the toxic side effects of currently employed therapeutic agents.Keywords
This publication has 50 references indexed in Scilit:
- Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancerProceedings of the National Academy of Sciences, 2006
- Enhanced Expression of the Inorganic Phosphate Transporter Pit-1 Is Involved in BMP-2–Induced Matrix Mineralization in Osteoblast-Like CellsJournal of Bone and Mineral Research, 2006
- Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathwaysOncogene, 2006
- Inhibition of Tumor Growth, Angiogenesis, and Tumor Cell Proliferation by a Small Molecule Inhibitor of c-Jun N-terminal KinaseThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125The EMBO Journal, 2004
- Protein Kinase C-independent Activation of Protein Kinase D Is Involved in BMP-2-induced Activation of Stress Mitogen-activated Protein Kinases JNK and p38 and Osteoblastic Cell DifferentiationJournal of Biological Chemistry, 2004
- Requirement of Bmpr1a for Müllerian duct regression during male sexual developmentNature Genetics, 2002
- Mullerian Inhibiting Substance Signaling Uses a Bone Morphogenetic Protein (BMP)-Like Pathway Mediated by ALK2 and Induces Smad6 ExpressionMolecular Endocrinology, 2001
- p120 GAP Modulates Ras Activation of Jun Kinases and TransformationJournal of Biological Chemistry, 1997
- Opposing Effects of ERK and JNK-p38 MAP Kinases on ApoptosisScience, 1995